AUTO6NG

About Autolus Therapeutics

Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.

Therapeutic Areas